[Diabetic neuropathy and diabetic foot syndrome (update 2023)].

Diabetische Neuropathie und diabetischer Fuß (Update 2023).

Journal

Wiener klinische Wochenschrift
ISSN: 1613-7671
Titre abrégé: Wien Klin Wochenschr
Pays: Austria
ID NLM: 21620870R

Informations de publication

Date de publication:
Jan 2023
Historique:
accepted: 22 02 2023
medline: 28 4 2023
pubmed: 27 4 2023
entrez: 26 4 2023
Statut: ppublish

Résumé

These are the guidelines for diagnosis and treatment of diabetic neuropathy and diabetic foot.The position statement summarizes characteristic clinical symptoms and techniques for diagnostic assessment of diabetic neuropathy, including the complex situation of the diabetic foot syndrome. Recommendations for the therapeutic management of diabetic neuropathy, especially for the control of pain in sensorimotor neuropathy, are provided. The needs to prevent and treat diabetic foot syndrome are summarized. Der Begriff der diabetischen Neuropathie ist eine Sammelbezeichnung für Erkrankungen des peripheren Nervensystems die als Spätkomplikation des Diabetes mellitus auftreten.Die Leitlinienempfehlungen beschreiben die klinischen Symptome und diagnostischen Möglichkeiten, sowie die Therapiemaßnahmen insbesondere bei der schmerzhaften Form der sensomotorischen Neuropathie, einschließlich der komplexen Problematik des diabetischen Fußes.

Autres résumés

Type: Publisher (ger)
Der Begriff der diabetischen Neuropathie ist eine Sammelbezeichnung für Erkrankungen des peripheren Nervensystems die als Spätkomplikation des Diabetes mellitus auftreten.Die Leitlinienempfehlungen beschreiben die klinischen Symptome und diagnostischen Möglichkeiten, sowie die Therapiemaßnahmen insbesondere bei der schmerzhaften Form der sensomotorischen Neuropathie, einschließlich der komplexen Problematik des diabetischen Fußes.

Identifiants

pubmed: 37101039
doi: 10.1007/s00508-023-02167-7
pii: 10.1007/s00508-023-02167-7
pmc: PMC10133034
doi:

Types de publication

English Abstract Journal Article

Langues

ger

Sous-ensembles de citation

IM

Pagination

164-181

Informations de copyright

© 2023. The Author(s).

Références

American Diabetes Association. 10. Microvascular complications and foot care: Standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):105–18.
doi: 10.2337/dc18-S010
Feldman EL, Callaghan BC, Pop-Busui R, Zochodne DW, Wright DE, Bennett DL, et al. Diabetic neuropathy. Nat Rev Dis Primers. 2019;5(1):41.
pubmed: 31197153 doi: 10.1038/s41572-019-0092-1
Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012;11(6):521–34.
pmcid: 4254767 doi: 10.1016/S1474-4422(12)70065-0
Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993;36(2):150–4.
pubmed: 8458529 doi: 10.1007/BF00400697
Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A, KORA Study Group. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Med. 2009;10(2):393–400.
pubmed: 19207236 doi: 10.1111/j.1526-4637.2008.00555.x
Maser RE, Steenkiste AR, Dorman JS, Nielsen VK, Bass EB, Manjoo Q, et al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes. 1989;38(11):1456–61.
pubmed: 2620781 doi: 10.2337/diab.38.11.1456
Dyck PJ, Karnes JL, O’Brien PC, Litchy WJ, Low PA, Melton LJ. The Rochester Diabetic Neuropathy Study: Reassessment of tests and criteria for diagnosis and staged severity. Neurology. 1992;42(6):1164–70.
pubmed: 1603343 doi: 10.1212/WNL.42.6.1164
Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993;43(4):817–24.
pubmed: 8469345 doi: 10.1212/WNL.43.4.817
van de Poll-Franse LV, Valk GD, Renders CM, Heine RJ, van Eijk JTM. Longitudinal assessment of the development of diabetic polyneuropathy and associated risk factors. Diabet Med. 2002;19(9):771–6.
pubmed: 12207815 doi: 10.1046/j.1464-5491.2002.00778.x
Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev. 2012;28(Suppl 1):8–14.
pubmed: 22271716 doi: 10.1002/dmrr.2239
Sima AA, Sugimoto K. Experimental diabetic neuropathy: an update. Diabetologia. 1999;42(7):773–88.
pubmed: 10440118 doi: 10.1007/s001250051227
Vincent AM, Callaghan BC, Smith AL, Feldman EL. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol. 2011;7(10):573–83.
pubmed: 21912405 doi: 10.1038/nrneurol.2011.137
Yagihashi S, Yamagishi SI, Wada RR, Baba M, Hohman TC, Yabe-Nishimura C, et al. Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor. Brain. 2001;124(Pt 12):2448–58.
pubmed: 11701599 doi: 10.1093/brain/124.12.2448
Hoeldtke RD, Bryner KD, VanDyke K. Oxidative stress and autonomic nerve function in early type 1 diabetes. Clin Auton Res. 2011;21(1):19–28.
pubmed: 20872157 doi: 10.1007/s10286-010-0084-4
Khan A, Shafiq I, Hassan Shah M. Prevalence of vitamin B12 deficiency in patients with type II diabetes mellitus on metformin: A study from Khyber Pakhtunkhwa. Cureus. 2017;9(8):e1577.
pubmed: 29057189 pmcid: 5647126
Alharbi TJ, Tourkmani AM, Abdelhay O, Alkhashan HI, Al-Asmari AK, Bin Rsheed AM, et al. The association of metformin use with vitamin B12 deficiency and peripheral neuropathy in Saudi individuals with type 2 diabetes mellitus. PLoS ONE. 2018;13(10):e204420.
pubmed: 30321183 pmcid: 6188756 doi: 10.1371/journal.pone.0204420
Clodi M, Abrahamian H, Brath H, Brix J, Drexel H, Fasching P, et al. Antihyperglycemic treatment guidelines for diabetes mellitus type 2 (Update 2019). Wien Klin Wochenschr. 2019;131(Suppl 1):27–38.
pubmed: 30980148 doi: 10.1007/s00508-019-1471-z
Ziegler D. Diagnosis and treatment of diabetic autonomic neuropathy. Curr Diab Rep. 2001;1(3):216–27.
pubmed: 12643202 doi: 10.1007/s11892-001-0037-3
Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26(5):1553–79.
pubmed: 12716821 doi: 10.2337/diacare.26.5.1553
Tesfaye S, Vileikyte L, Rayman G, Sindrup SH, Perkins BA, Baconja M, et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011;27(7):629–38.
pubmed: 21695762 doi: 10.1002/dmrr.1225
Mueller MJ. Identifying patients with diabetes mellitus who are at risk for lower-extremity complications: use of Semmes-Weinstein monofilaments. Phys Ther. 1996;76(1):68–71.
pubmed: 8545495 doi: 10.1093/ptj/76.1.68
Meijer JWG, Bosma E, Lefrandt JD, Links TP, Smit AJ, Stewart RE, et al. Clinical diagnosis of diabetic polyneuropathy with the diabetic neuropathy symptom and diabetic neuropathy examination scores. Diabetes Care. 2003;26(3):697–701.
pubmed: 12610024 doi: 10.2337/diacare.26.3.697
Rahman M, Griffin SJ, Rathmann W, Wareham NJ. How should peripheral neuropathy be assessed in people with diabetes in primary care? A population-based comparison of four measures. Diabet Med. 2003;20(5):368–74.
pubmed: 12752485 doi: 10.1046/j.1464-5491.2003.00931.x
Bolton CF, Remtulla H, Toth B, Bernardi L, Lindsay RM, Maryniak O, et al. Distinctive electrophysiological features of denervated muscle in uremic patients. J Clin Neurophysiol. 1997;14(6):539–42.
pubmed: 9458061 doi: 10.1097/00004691-199711000-00011
Kofler M, Leis AA, Valls-Solé J. Cutaneous silent periods—Part 1: Update on physiological mechanisms. Clin Neurophysiol. 2019;130(4):588–603.
pubmed: 30691969 doi: 10.1016/j.clinph.2019.01.002
Casanova-Molla J, Valls-Solé J. Electrodiagnostic testing of small fiber neuropathies: A review of existing guidelines. J Clin Neurophysiol. 2020;37(4):288–93.
pubmed: 33151659 doi: 10.1097/WNP.0000000000000681
Lauria G, Hsieh ST, Johansson O, Kennedy WR, Leger JM, Mellgren SI, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol. 2010;17(7):903–e49.
pubmed: 20642627 doi: 10.1111/j.1468-1331.2010.03023.x
Malik RA, Kallinikos P, Abbott CA, van Schie CHM, Morgan P, Efron N, et al. Corneal confocal microscopy: a non-invasive surrogate of nerve fibre damage and repair in diabetic patients. Diabetologia. 2003;46(5):683–8.
pubmed: 12739016 doi: 10.1007/s00125-003-1086-8
Kulzer B, Albus C, Herpertz S, Kruse J, Lange K, Lederbogen F, et al. Psychosocial factors and diabetes. Exp Clin Endocrinol Diabetes. 2021;129(S 01):S91–105.
pubmed: 34384123 doi: 10.1055/a-1284-6524
Abrahamian H, Kautzky-Willer A, Rießland-Seifert A, Fasching P, Ebenbichler C, Kautzky A, et al. Psychische Erkrankungen und Diabetes mellitus (Update 2019). Wien Klin Wochenschr. 2019;131(1):186–95.
pubmed: 30980168 doi: 10.1007/s00508-019-1458-9
Morbach S, Lobmann R, Eckhard M, Müller E, Reike H, Risse A, et al. Diabetisches Fußsyndrom. Diabetol Stoffwechsel. 2020;15(S 1):S206–15.
Lu Y, Xing P, Cai X, Luo D, Li R, Lloyd C, et al. Prevalence and risk factors for diabetic peripheral neuropathy in type 2 diabetic patients from 14 countries: Estimates of the INTERPRET-DD study. Front Public Health. 2020;8:534372.
pubmed: 33194943 pmcid: 7606804 doi: 10.3389/fpubh.2020.534372
Vas PRJ, Papanas N. Diabetic peripheral neuropathy and depression: dancing with wolves?—Mini-review and commentary on Alghafri et al. “Screening for depressive symptoms amongst patients with diabetic peripheral neuropathy”. Rev Diabet Stud. 2021;17(1):17–20.
pubmed: 34289002 pmcid: 9380099 doi: 10.1900/RDS.2021.17.17
Elgendy R, Deschênes SS, Burns RJ, Levy M, Schmitz N. Alcohol consumption, depressive symptoms, and the incidence of diabetes-related complications. J Diabetes. 2019;11(1):14–22.
pubmed: 29989328 doi: 10.1111/1753-0407.12822
American Diabetes Association Professional Practice Committee. 12. Retinopathy, neuropathy, and foot care: Standards of medical care in diabetes—2022. Diabetes Care. 2021;45(Supplement_1):S185–S94.
doi: 10.2337/dc22-S012
Gillhausen K, Freynhagen R, Maihöfner C. DIAGNOSE UND THERAPIE NEUROPATHISCHER SCHMERZEN:EINE PRAKTISCHE HILFE FÜR DEN HAUSÄRZTLICHEN ALLTAG. https://docplayer.org/123308213-Diagnose-und-therapie-neuropathischer-schmerzen.html . Zugegriffen: 30. Okt. 2022.
Schlereth T. Diagnose und nicht interventionelle Therapie neuropathischer Schmerzen, S2k-Leitlinie, 2019. Deutsche Gesellschaft für Neurologie. https://dgn.org/leitlinien . Zugegriffen: 30. Okt. 2022, (Leitlinien für Diagnostik und Therapie in der Neurologie).
Graggober G, et al. CHRONISCHE PERIPHERE NEUROPATHISCHE SCHMERZEN: Diagnose und Therapie in der Praxis. Schmerz Nachrichten, Bd. 1d. 2020.
Attal N. Pharmacological treatments of neuropathic pain: The latest recommendations. Rev Neurol (Paris). 2019;175(1–2):46–50.
pubmed: 30318260 doi: 10.1016/j.neurol.2018.08.005
Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49(10):661–9.
pubmed: 20818832 doi: 10.2165/11536200-000000000-00000
Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–73.
pubmed: 25575710 pmcid: 4493167 doi: 10.1016/S1474-4422(14)70251-0
Freynhagen R, Baron R, Kawaguchi Y, Malik RA, Martire DL, Parsons B, et al. Pregabalin for neuropathic pain in primary care settings: recommendations for dosing and titration. Postgrad Med. 2021;133(1):1–9.
pubmed: 33423590 doi: 10.1080/00325481.2020.1857992
González-Duarte A, Lem M, Díaz-Díaz E, Castillo C, Cárdenas-Soto K. The efficacy of pregabalin in the treatment of prediabetic neuropathic pain. Clin J Pain. 2016;32(11):927–32.
pubmed: 26670614 doi: 10.1097/AJP.0000000000000339
Wiffen PJ, Derry S, Bell RF, Rice AS, Tölle TR, Phillips T, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017; https://doi.org/10.1002/14651858.CD007938.pub4/full .
doi: 10.1002/14651858.CD007938.pub4/full pubmed: 28779491 pmcid: 6424379
Moore A, Derry S, Wiffen P. Gabapentin for chronic neuropathic pain. JAMA. 2018;319:818.
pubmed: 29486015 doi: 10.1001/jama.2017.21547
PharmNet.Bund. PharmNet.Bund – Arzneimittel-Informationssystem. https://www.pharmnet-bund.de/dynamic/de/arzneimittel-informationssystem/index.html . Zugegriffen: 30. Okt. 2022.
Ziegler D, Keller J, Maier C, Pannek J. Diabetische Neuropathie. Diabetol Stoffwechs. 2021;16(Suppl 2):S336–S50.
Rull JA, Quibrera R, González-Millán H, Lozano Castañeda O. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double blind crossover trial. Diabetologia. 1969;5(4):215–8.
pubmed: 4902717 doi: 10.1007/BF01212087
Sachau J, Fabig SC, Rehm S, Baron R. Therapie der Polyneuropathie—autonome Symptome und Schmerzen. Internist. 2020;61(3):270–6.
pubmed: 32030435 doi: 10.1007/s00108-020-00739-7
Wiffen PJ, Derry S, Moore RA. Lamotrigine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2013;12:CD6044.
Redaktion Deutsches Ärzteblatt DÄG. Pharmakotherapie chronischer neuropathischer Schmerzen. Deutsches Ärzteblatt. 2016. https://www.aerzteblatt.de/archiv/181963/Pharmakotherapie-chronischer-neuropathischer-Schmerzen . Zugegriffen: 30. Okt. 2022.
Baron R, Koppert W, Strumpf M, Willweber-Strumpf A. Interdisziplinäre Diagnostik – multimodaleTherapie. In: Praktische Schmerzmedizin. 4. Aufl. Berlin, Heidelberg: Springer; 2019.
doi: 10.1007/978-3-662-57487-4
Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain in adults. Cochrane Database Syst Rev. 2015;7:CD8242.
Griebeler ML, Morey-Vargas OL, Brito JP, Tsapas A, Wang Z, Carranza Leon BG, et al. Pharmacologic interventions for painful diabetic neuropathy: An umbrella systematic review and comparative effectiveness network meta-analysis. Ann Intern Med. 2014;161(9):639–49.
pubmed: 25364885 doi: 10.7326/M14-0511
Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116(1–2):109–18.
pubmed: 15927394 doi: 10.1016/j.pain.2005.03.029
Kajdasz DK, Iyengar S, Desaiah D, Backonja MM, Farrar JT, Fishbain DA, et al. Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. Clin Ther. 2007;29(Suppl):2536–46.
pubmed: 18164920 doi: 10.1016/j.clinthera.2007.12.002
Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurol. 2008;8:29.
pubmed: 18673529 pmcid: 2529342 doi: 10.1186/1471-2377-8-29
Lunn MPT, Hughes RAC, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014;1:CD7115.
Durand JP, Deplanque G, Montheil V, Gornet JM, Scotte F, Mir O, et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2012;23(1):200–5.
pubmed: 21427067 doi: 10.1093/annonc/mdr045
Häuser W, Bock F, Engeser P, Hege-Scheuing G, Hüppe M, Lindena G, et al. Recommendations of the updated LONTS guidelines. Long-term opioid therapy for chronic noncancer pain. Schmerz. 2015;29(1):109–30.
pubmed: 25616996 doi: 10.1007/s00482-014-1463-x
Gelbe Liste. Gelbe Liste Pharmindex Online. 2022. https://www.gelbe-liste.de/ . Zugegriffen: 30. Okt. 2022.
Duehmke RM, Derry S, Wiffen PJ, Bell RF, Aldington D, Moore RA. Tramadol for neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6:CD3726.
pubmed: 28616956
Schwartz S, Etropolski MS, Shapiro DY, Rauschkolb C, Vinik AI, Lange B, et al. A pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathy. Clin Drug Investig. 2015;35(2):95–108.
pubmed: 25503082 doi: 10.1007/s40261-014-0249-3
Häuser W, Finn DP, Kalso E, Krcevski-Skvarc N, Kress HG, Morlion B, et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. Eur J Pain. 2018;22(9):1547–64.
pubmed: 30074291 doi: 10.1002/ejp.1297
Çakici N, Fakkel TM, van Neck JW, Verhagen AP, Coert JH. Systematic review of treatments for diabetic peripheral neuropathy. Diabet Med. 2016;33(11):1466–76.
pubmed: 26822889 doi: 10.1111/dme.13083
Moore RA, Chi CC, Wiffen PJ, Derry S, Rice ASC. Oral nonsteroidal anti-inflammatory drugs for neuropathic pain. Cochrane Database Syst Rev. 2015;5(10):CD10902.
Maihöfner CG, Heskamp MLS. Treatment of peripheral neuropathic pain by topical capsaicin: Impact of pre-existing pain in the QUEPP-study. Eur J Pain. 2014;18(5):671–9.
pubmed: 24259265 doi: 10.1002/j.1532-2149.2013.00415.x
Prudhomme M, Legras A, Delorme C, Lansaman T, Lanteri-Minet M, Medioni J, et al. Management of neuropathic pain induced by surgery: Review of the literature by a group of experts specialized in pain management, anesthesia and surgery. J Visc Surg. 2020;157(1):43–52.
pubmed: 31668838 doi: 10.1016/j.jviscsurg.2019.09.004
van Nooten F, Treur M, Pantiri K, Stoker M, Charokopou M. Capsaicin 8 % patch versus oral neuropathic pain medications for the treatment of painful diabetic peripheral neuropathy: a systematic literature review and network meta-analysis. Clin Ther. 2017;39(4):787–803.e18.
pubmed: 28365034 doi: 10.1016/j.clinthera.2017.02.010
Fachinformation-Qutenza. https://www.ema.europa.eu/en/documents/product-information/qutenza-epar-product-information_de.pdf . Zugegriffen: Internet.
Gibson W, Wand BM, O’Connell NE. Transcutaneous electrical nerve stimulation (TENS) for neuropathic pain in adults. Cochrane Database Syst Rev. 2017;9:CD11976.
pubmed: 28905362
Sommer C, Geber C, Young P, Forst R, Birklein F, Schoser B. Polyneuropathies. Dtsch Arztebl Int. 2018;115(6):83–90.
pubmed: 29478436 pmcid: 5832891
Bao T, Patil S, Chen C, Zhi IW, Li QS, Piulson L, et al. Effect of acupuncture vs sham procedure on chemotherapy-induced peripheral neuropathy symptoms: a randomized clinical trial. JAMA Netw Open. 2020;3(3):e200681.
pubmed: 32159808 pmcid: 7066475 doi: 10.1001/jamanetworkopen.2020.0681
Chen W, Yang GY, Liu B, Manheimer E, Liu JP. Manual acupuncture for treatment of diabetic peripheral neuropathy: a systematic review of randomized controlled trials. PLoS One. 2013;8(9):e73764.
pubmed: 24069229 pmcid: 3771980 doi: 10.1371/journal.pone.0073764
Wolter T. Spinal cord stimulation for neuropathic pain: current perspectives. J Pain Res. 2014;7:651–63.
pubmed: 25429237 pmcid: 4242499 doi: 10.2147/JPR.S37589
Thakral G, Kim PJ, LaFontaine J, Menzies R, Najafi B, Lavery LA. Electrical stimulation as an adjunctive treatment of painful and sensory diabetic neuropathy. J Diabetes Sci Technol. 2013;7(5):1202–9.
pubmed: 24124947 pmcid: 3876364 doi: 10.1177/193229681300700510
Sun L, Peng C, Joosten E, Cheung CW, Tan F, Jiang W, et al. Spinal cord stimulation and treatment of peripheral or central Neuropathic pain: Mechanisms and clinical application. Neural Plast. 2021;2021:5607898.
pubmed: 34721569 pmcid: 8553441 doi: 10.1155/2021/5607898
Chapman KB, Groenen PS, Patel KV, Vissers KC, van Helmond N. T12 dorsal root ganglion stimulation to treat chronic low back pain: a case series. Neuromodulation. 2020;23(2):203–12.
pubmed: 31588662 doi: 10.1111/ner.13047
Potter ST, Welch S, Tata F, Probert S, Nagpal A. Dorsal root ganglion stimulation. Phys Med Rehabil Clin N Am. 2022;33(2):359–78.
pubmed: 35526975 doi: 10.1016/j.pmr.2022.02.005
AWMF. Nationale VersorgungsrichtLeitlinie (NVL) Neuropahie bei Diabetes im Erwachsenenalter – Kurzfassung. 1. Aufl. 2012. Version 3, AWMF-Register-Nr.: nvl-001e.
Ziegler D, Gries FA, Spüler M, Lessmann F. The epidemiology of diabetic neuropathy. Diabetic Cardiovascular Autonomic Neuropathy Multicenter Study Group. J Diabetes Complications. 1992;6(1):49–57.
pubmed: 1562759 doi: 10.1016/1056-8727(92)90049-Q
ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72.
doi: 10.1056/NEJMoa0802987
Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005;293(2):217–28.
pubmed: 15644549 doi: 10.1001/jama.293.2.217
Aboyans V, Ricco JB, Bartelink MLEL, Björck M, Brodmann M, Cohnert T, et al. 2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763–816.
pubmed: 28886620 doi: 10.1093/eurheartj/ehx095
Schaper NC, Andros G, Apelqvist J, Bakker K, Lammer J, Lepantalo M, et al. Specific guidelines for the diagnosis and treatment of peripheral arterial disease in a patient with diabetes and ulceration of the foot 2011. Diabetes Metab Res Rev. 2012;28(Suppl 1):236–7.
pubmed: 22271745 doi: 10.1002/dmrr.2252
Schaper NC, Netten JJ, Apelqvist J, Bus SA, Hinchliffe RJ, Lipsky BA, et al. Practical Guidelines on the prevention and management of diabetic foot disease (IWGDF 2019 update). Diabetes Metab Res Rev. 2020; https://doi.org/10.1002/dmrr.3266 .
doi: 10.1002/dmrr.3266 pubmed: 32176448 pmcid: 7154668
Ince P, Abbas ZG, Lutale JK, Basit A, Ali SM, Chohan F, et al. Use of the SINBAD classification system and score in comparing outcome of foot ulcer management on three continents. Diabetes Care. 2008;31(5):964–7.
pubmed: 18299441 doi: 10.2337/dc07-2367
Morbach S, Müller E, Reike H, Risse A, Rümenapf G, Spraul M, et al. Diabetic foot syndrome. Exp Clin Endocrinol Diabetes. 2014;122(7):416–24.
pubmed: 25014093 doi: 10.1055/s-0034-1366455
Małecki R, Rosiński K, Adamiec R. Etiological factors of infections in diabetic foot syndrome—Attempt to define optimal empirical therapy. Adv Clin Exp Med. 2014;23(1):39–48.
pubmed: 24596002 doi: 10.17219/acem/37020
Game FL, Hinchliffe RJ, Apelqvist J, Armstrong DG, Bakker K, Hartemann A, et al. A systematic review of interventions to enhance the healing of chronic ulcers of the foot in diabetes. Diabetes Metab Res Rev. 2012;28(Suppl 1):119–41.
pubmed: 22271737 doi: 10.1002/dmrr.2246
Rayman G, Vas P, Dhatariya K, Driver V, Hartemann A, Londahl M, et al. Guidelines on use of interventions to enhance healing of chronic foot ulcers in diabetes (IWGDF 2019 update). Diabetes Metab Res Rev. 2020;36(Suppl 1):e3283.
pubmed: 32176450
Dumville JC, Lipsky BA, Hoey C, Cruciani M, Fiscon M, Xia J. Topical antimicrobial agents for treating foot ulcers in people with diabetes. Cochrane Database Syst Rev. 2017;6:CD11038.
pubmed: 28613416
Edmonds M, Lázaro-Martínez JL, Alfayate-García JM, Martini J, Petit JM, Rayman G, et al. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol. 2018;6(3):186–96.
pubmed: 29275068 doi: 10.1016/S2213-8587(17)30438-2
Santema TBK, Poyck PPC, Ubbink DT. Systematic review and meta-analysis of skin substitutes in the treatment of diabetic foot ulcers: Highlights of a Cochrane systematic review. Wound Repair Regen. 2016;24(4):737–44.
pubmed: 27062201 doi: 10.1111/wrr.12434
Hitchman LH, Totty JP, Raza A, Cai P, Smith GE, Carradice D, et al. Extracorporeal shockwave therapy for diabetic foot ulcers: a systematic review and meta-analysis. Ann Vasc Surg. 2019;56:330–9.
pubmed: 30496896 doi: 10.1016/j.avsg.2018.10.013
Huang Q, Yan P, Xiong H, Shuai T, Liu J, Zhu L, et al. Extracorporeal shock wave therapy for treating foot ulcers in adults with type 1 and type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Can J Diabetes. 2020;44(2):196–204.e3.
pubmed: 31515158 doi: 10.1016/j.jcjd.2019.05.006
Short DJ, Zgonis T. Management of osteomyelitis and bone loss in the diabetic charcot foot and ankle. Clin Podiatr Med Surg. 2017;34(3):381–7.
pubmed: 28576196 doi: 10.1016/j.cpm.2017.02.008
Sanders L, Frykberg R. Charcot neuroarthropathy of the foot. In: Levin and O’Neals’s the diabetic foot. 2001. S. 439–66.

Auteurs

Gerd Köhler (G)

Klinische Abteilung für Endokrinologie und Diabetologie, Medizinische Universität Graz, Graz, Österreich. gerd.koehler@medunigraz.at.
Rehabilitationszentrum Aflenz für Stoffwechselerkrankungen mit Schwerpunkt Diabetes mellitus und hochgradige Adipositas, Aflenz, Österreich. gerd.koehler@medunigraz.at.

Marlies Eichner (M)

Klinik Hietzing, Wien, Österreich.

Heidemarie Abrahamian (H)

Internistische & Endokrinologische Ordination, Wien, Österreich.

Markus Kofler (M)

Abteilung für Neurologie, Landeskrankenhaus Hochzirl, Hochzirl-Natters, Österreich.

Wolfgang Sturm (W)

Universitätsklinik für Innere Medizin I Innsbruck, Innsbruck, Österreich.

Anja Menzel (A)

Innere Medizin, Endokrinologie und Diabetologie, Deutschlandsberg, Österreich.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH